Gluvedus (Metformin Hydrochloride, Vildagliptin)

Gluvedus is indicated for the management of type 2 diabetes mellitus, typically when diet, exercise, and monotherapy are insufficient. It may be prescribed as part of a comprehensive treatment plan that includes lifestyle modifications.

• Adjunct to diet and exercise in adults with type 2 diabetes.
• Combination therapy when metformin alone does not achieve glycemic targets.
• Used in patients requiring both insulin sensitization and incretin‑based effects.
• May be considered when a single‑pill regimen is preferred for adherence.
• Often prescribed alongside other antihyperglycemic agents as needed.

Side effects of Gluvedus vary in frequency and severity. Common reactions are usually mild and transient, while serious events are less frequent but require medical attention.

Common

• Nausea or upset stomach
• Diarrhea or loose stools
• Headache
• Upper respiratory tract infection symptoms
• Mild hypoglycemia (especially with concomitant sulfonylureas)

Serious

• Lactic acidosis (rare, associated with metformin)
• Severe hypoglycemia
• Pancreatitis
• Severe allergic reactions such as rash or angioedema
• Hepatic dysfunction

Before starting Gluvedus, certain health considerations should be reviewed. Patients and clinicians should be aware of the following precautions:

• Assess renal function; avoid use in severe renal impairment.
• Monitor liver enzymes periodically, especially in patients with hepatic disease.
• Evaluate risk of lactic acidosis, particularly in conditions that predispose to hypoxia.
• Use caution in elderly patients due to increased susceptibility to adverse effects.
• Discontinue before any radiographic studies involving iodinated contrast agents.
• Counsel women of childbearing potential about unknown pregnancy safety.

Gluvedus can interact with several drug classes, influencing its efficacy or safety profile. Interactions are grouped by the level of risk.

Avoid

• Iodinated contrast media (risk of renal impairment and lactic acidosis).
• Strong CYP2C9 inhibitors that may increase vildagliptin levels.
• Alcohol excess, which can potentiate metformin‑related lactic acidosis.

Use with caution

• Sulfonylureas or insulin (increased risk of hypoglycemia).
• Diuretics that affect renal function.
• Corticosteroids, which may raise blood glucose levels.
• Other antihyperglycemic agents, requiring dose adjustments.